Taiwan · Delayed Price · Currency is TWD Welgene Biotech Statistics
Total Valuation
Welgene Biotech has a market cap or net worth of TWD 441.62 million. The enterprise value is 415.20 million.
| Market Cap | 441.62M |
| Enterprise Value | 415.20M |
Important Dates
The next estimated earnings date is Friday, November 7, 2025.
| Earnings Date | Nov 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Welgene Biotech has 23.30 million shares outstanding.
| Current Share Class | 23.30M |
| Shares Outstanding | 23.30M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 8.40% |
| Owned by Institutions (%) | n/a |
| Float | 7.19M |
Valuation Ratios
The trailing PE ratio is 192.09.
| PE Ratio | 192.09 |
| Forward PE | n/a |
| PS Ratio | 1.28 |
| PB Ratio | 1.54 |
| P/TBV Ratio | 1.56 |
| P/FCF Ratio | 7.46 |
| P/OCF Ratio | 6.81 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.72, with an EV/FCF ratio of 7.02.
| EV / Earnings | 180.60 |
| EV / Sales | 1.20 |
| EV / EBITDA | 14.72 |
| EV / EBIT | n/a |
| EV / FCF | 7.02 |
Financial Position
The company has a current ratio of 2.51, with a Debt / Equity ratio of 0.52.
| Current Ratio | 2.51 |
| Quick Ratio | 1.72 |
| Debt / Equity | 0.52 |
| Debt / EBITDA | 5.33 |
| Debt / FCF | 2.54 |
| Interest Coverage | 0.15 |
Financial Efficiency
Return on equity (ROE) is 0.56% and return on invested capital (ROIC) is 0.06%.
| Return on Equity (ROE) | 0.56% |
| Return on Assets (ROA) | 0.05% |
| Return on Invested Capital (ROIC) | 0.06% |
| Return on Capital Employed (ROCE) | 0.11% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.65 |
| Inventory Turnover | 3.81 |
Taxes
In the past 12 months, Welgene Biotech has paid 782,000 in taxes.
| Income Tax | 782,000 |
| Effective Tax Rate | 32.37% |
Stock Price Statistics
The stock price has decreased by -19.70% in the last 52 weeks. The beta is 0.32, so Welgene Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | -19.70% |
| 50-Day Moving Average | 21.00 |
| 200-Day Moving Average | 21.31 |
| Relative Strength Index (RSI) | 32.11 |
| Average Volume (20 Days) | 22,586 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Welgene Biotech had revenue of TWD 346.12 million and earned 2.30 million in profits. Earnings per share was 0.10.
| Revenue | 346.12M |
| Gross Profit | 146.82M |
| Operating Income | 452,000 |
| Pretax Income | 2.42M |
| Net Income | 2.30M |
| EBITDA | 14.89M |
| EBIT | 452,000 |
| Earnings Per Share (EPS) | 0.10 |
Balance Sheet
The company has 181.20 million in cash and 150.38 million in debt, giving a net cash position of 30.82 million or 1.32 per share.
| Cash & Cash Equivalents | 181.20M |
| Total Debt | 150.38M |
| Net Cash | 30.82M |
| Net Cash Per Share | 1.32 |
| Equity (Book Value) | 287.19M |
| Book Value Per Share | 12.13 |
| Working Capital | 201.10M |
Cash Flow
In the last 12 months, operating cash flow was 64.81 million and capital expenditures -5.65 million, giving a free cash flow of 59.16 million.
| Operating Cash Flow | 64.81M |
| Capital Expenditures | -5.65M |
| Free Cash Flow | 59.16M |
| FCF Per Share | 2.54 |
Margins
Gross margin is 42.42%, with operating and profit margins of 0.13% and 0.66%.
| Gross Margin | 42.42% |
| Operating Margin | 0.13% |
| Pretax Margin | 0.70% |
| Profit Margin | 0.66% |
| EBITDA Margin | 4.30% |
| EBIT Margin | 0.13% |
| FCF Margin | 17.09% |
Dividends & Yields
Welgene Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 0.52% |
| FCF Yield | 13.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 17, 2018. It was a forward split with a ratio of 1.08.
| Last Split Date | Aug 17, 2018 |
| Split Type | Forward |
| Split Ratio | 1.08 |
Scores
Welgene Biotech has an Altman Z-Score of 2.52 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.52 |
| Piotroski F-Score | 7 |